Pharmaceuticals & Life Sciences · Preclinical Development

Preclinical Safety & Toxicology Studies

Enhances→Stable

1–3 Years

1–3 years. Pilots and early adopters exist. Enterprise adoption accelerating but not mainstream.

Trajectories describe the observable direction of human effort — not a prediction about specific roles, headcount, or individual careers.

What You Do Today

Design and oversee GLP toxicology studies — single-dose, repeat-dose, genotoxicity, reproductive toxicity, carcinogenicity. Select species, dose levels, and study durations per ICH guidelines. Analyze pathology data and write toxicology summaries for regulatory submissions.

AI Technologies

Predictive Toxicology MLDigital Pathology AIOrgan-on-Chip ModelingRead-Across Algorithms

Roles Involved

Who works on this

Digital Transformation LeaderInnovation LeadResearch ScientistFormulation ScientistTechnical WriterProject Manager

VP/SVPDirectorIndividual ContributorCross-Functional

How It Works

ML models predict toxicity endpoints from molecular structure and in vitro data, enabling earlier go/no-go decisions. Digital pathology AI analyzes tissue slides at scale, detecting subtle findings that human pathologists might miss or disagree on. Organ-on-chip platforms generate human-relevant tox data.

What Changes

Early toxicity prediction improves kill decisions — AI identifies likely tox liabilities before committing to expensive GLP studies. Digital pathology provides more consistent and quantitative assessments.

What Stays the Same

Designing studies that satisfy regulatory requirements, interpreting findings in the context of the therapeutic indication, and making the risk-benefit judgment to advance or kill a candidate require experienced toxicologists.

Cross-Industry Concepts

predictive safety image analysis risk assessment

Evidence & Sources

•FDA predictive toxicology pilot programs
•ICH S1B(R1) carcinogenicity guidelines

Sources listed are directional references, not formal citations. Verify against primary sources before using in business cases or presentations.

Last reviewed: March 2026

What To Do Next

This section won't tell you what your numbers should be. It will show you how to find them yourself. Every instruction below produces a real, verifiable result in your organization. No benchmarks, no projections — just the steps to build your own evidence.

Establish Your Baseline

Know where you are before you move

Before adopting AI tools for preclinical safety & toxicology studies, document your current state in preclinical development.

•

Map your current process: Document how preclinical safety & toxicology studies works today — who does what, how long each step takes, and where the bottlenecks are. Use your EHR system data to establish a factual baseline.

•

Identify the judgment calls: Designing studies that satisfy regulatory requirements, interpreting findings in the context of the therapeutic indication, and making the risk-benefit judgment to advance or kill a candidate require experienced toxicologists. — these are the boundaries AI won't cross. Know them before you start.

•

Check your data readiness: AI tools for preclinical development need clean, accessible data. Check whether your EHR system has the historical data, integrations, and quality to support Predictive Toxicology ML tools.

Without a baseline, you can't tell whether AI actually improved preclinical safety & toxicology studies or just changed who does it.

Define Your Measures

What to track and how to calculate it

patient outcomes

How to calculate

Measure patient outcomes for preclinical safety & toxicology studies before and after AI adoption. Pull from your EHR system.

Why it matters

This is the most direct indicator of whether AI is adding value to preclinical development.

clinical documentation quality

How to calculate

Track clinical documentation quality using the same methodology you use today. Don't change how you measure just because you changed how you work.

Why it matters

Speed without quality is just faster mistakes. Measure both together.

When to check: Check after 30 days of consistent use, then quarterly.

The commitment: Give new tools at least 30 days before judging. The first week is always awkward.

What NOT to measure: Don't measure AI adoption rate as a goal. Measure outcomes. If the tool helps with preclinical safety & toxicology studies, people will use it.